Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q1 2022 Earnings Presentation
8 slides from Quanterix's earnings presentation, May 10, 2022
Slide 1: Q1 2022 Earnings Call
Q1 2022 Earnings Call M AY 1 0 t h , 2 0 2 2
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as wel
Slide 3: Q1 2022 Results – 3 yr CAGR
Q1 2022 Earnings Call Q1 2022 Results – 3 yr CAGR Q1 2021 Q1 2022 OTHER INSTRUMENTS CONSUMABLES ACCELERATOR RADx SERVICES Q1 2022 Revenue 27.2 29.6 Mix 21% 49% 21% n/a 9% 3-yr CAGR 22% 33% 61% n/a 27% GM $ 16.3 14.6 Q1 2021 Q1 2022 +27.9% GM % 60.1% 49.3% 14.4 -10.6% 11.3 +45.2% 7.0 6.2 6.2 +12.0% •
Slide 4: Q1 2022 Revenue Stratification
EXECUTIVE SESSION 1 Q1 2022 Revenue Stratification 11% 12% 52% 6% 21% 21% 25% PRODUCTS G E O G R AP H Y CUSTOMER D I S E AS E S & SERVICES 63% 48% 82% 49% Yo Y Yo Y Yo Y Yo Y GROWTH GROWTH GROWTH GROWTH NA +18% Pharma / CROs +46% Neurology +77% Consumables +28% Europe -3% Academia +3% Oncology** 31%
Slide 5: Scientific Validation Driving Adoption
Q1 2022 Earnings Call Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others 2022 Advances PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements 506 # of units placed 480 41 Cumulative 750 1,726 41 708 117 78 1,575 46 73 113 187 403 44 177 17
Slide 6: Simoa Nf-L Levels Used to Establish Viral (EBV) Role in Causation of MS
Q1 2022 Earnings Call Simoa Nf-L Levels Used to Establish Viral (EBV) Role in Causation of MS Researchers used Simoa sNfL levels to show causative link between EB virus infection and MS Longitudinal study of 10 million US Military personal Risk of MS increased 32-fold after infection with EBV (b
Slide 7: Reference Data Base of NfL Levels for Individuals
Q1 2022 Earnings Call Reference Data Base of NfL Levels for Individuals Provides a key baseline for clinical applications NfL levels vary with age and BMI making them hard to use at the individual level Creation of a large (10,000+) reference database of age and BMI adjusted NfL level Developed sNfL
Slide 8: Q1 2022 P&L and Cash Change
Q1 2022 Earnings Call Q1 2022 P&L and Cash Change GROWTH In $m Q1 2022 Q1 2021 VAR. vs. PYR Instrument Revenue 6.2 -11% 7.0 -0.7 Consumables Revenue 14.4 +28% 11.3 +3.1 Product Revenue 20.7 +13% 18.2 +2.4 $m Cash Balance & Cash Usage Accelerator Services 6.2 +45% 4.3 +1.9 -22.1 Other Services 2.6 2.